NCT04257617View on ClinicalTrials.gov

A Trial of ZL-1201 in Subjects With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 11, 2020

Primary Completion Date

May 17, 2022

Study Completion Date

January 19, 2023

Conditions
Advanced Cancer
Interventions
DRUG

ZL-1201

Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.

Trial Locations (7)

11776

US2002, New York

32224

US2005, Jacksonville

55905

US2001, Rochester

63110

US2003, St Louis

85259

US2004, Phoenix

Unknown

CN1003, Chongqing

CN1002, Hangzhou

All Listed Sponsors
lead

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY

NCT04257617 - A Trial of ZL-1201 in Subjects With Advanced Cancer | Biotech Hunter | Biotech Hunter